Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy.

Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, Zacarias-Fluck MF, Casacuberta-Serra S, Serrano Del Pozo E, Fiore C, Foradada L, Cano VC, Sánchez-Hervás M, Guenther M, Romero Sanz E, Oteo M, Tremblay C, Martín G, Letourneau D, Montagne M, Morcillo Alonso MÁ, Whitfield JR, Lavigne P, Soucek L.

Sci Transl Med. 2019 Mar 20;11(484). pii: eaar5012. doi: 10.1126/scitranslmed.aar5012.

2.

Effect of cellular senescence on the growth of HER2-positive breast cancers.

Zacarias-Fluck MF, Morancho B, Vicario R, Luque Garcia A, Escorihuela M, Villanueva J, Rubio IT, Arribas J.

J Natl Cancer Inst. 2015 May 13;107(5). pii: djv020. doi: 10.1093/jnci/djv020. Print 2015 May.

PMID:
25972601
3.

A mammary adenocarcinoma murine model suitable for the study of cancer immunoediting.

Pagura L, Cáceres JM, Cardinale A, Scharovsky OG, Masso RJ, Zacarías-Fluck MF, Rico MJ, Rozados VR.

J Biomed Sci. 2014 May 30;21:52. doi: 10.1186/1423-0127-21-52.

4.

Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.

Angelini PD, Zacarias Fluck MF, Pedersen K, Parra-Palau JL, Guiu M, Bernadó Morales C, Vicario R, Luque-García A, Navalpotro NP, Giralt J, Canals F, Gomis RR, Tabernero J, Baselga J, Villanueva J, Arribas J.

Cancer Res. 2013 Jan 1;73(1):450-8. doi: 10.1158/0008-5472.CAN-12-2301. Erratum in: Cancer Res. 2013 Oct 1;73(19):6095.

5.

Regulatory T cells but not NKT I cells are modulated by a single low-dose cyclophosphamide in a B cell lymphoma tumor-model.

Rico MJ, Rozados VR, Mainetti LE, Zacarias Fluck MF, Matar P, Scharovsky OG.

Exp Oncol. 2012;34(1):38-42.

PMID:
22453147
6.

[Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].

Scharovsky OG, Matar P, Rozados VR, Rico MJ, Zacarías Fluck MF, Mainetti LE, Fernández Zenóbi MV, Roggero EA, Gervasoni SI, Rossa A, Perroud HA, Sánchez AM, Celoria GC, Font MT.

Medicina (B Aires). 2012;72(1):47-57. Spanish.

PMID:
22257459
7.

The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide.

Zacarías Fluck MF, Hess L, Salatino M, Croci DO, Stupirski JC, Di Masso RJ, Roggero E, Rabinovich GA, Scharovsky OG.

Cancer Immunol Immunother. 2012 Apr;61(4):469-80. doi: 10.1007/s00262-011-1114-3. Epub 2011 Sep 27.

PMID:
21947259
8.

The immune response and the therapeutic effect of metronomic chemotherapy with cyclophosphamide.

Rozados VR, Mainetti LE, Rico MJ, Zacarías Fluck MF, Matar P, Scharovsky OG.

Oncol Res. 2010;18(11-12):601-5.

PMID:
20939436
9.

Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment.

Croci DO, Zacarías Fluck MF, Rico MJ, Matar P, Rabinovich GA, Scharovsky OG.

Cancer Immunol Immunother. 2007 Nov;56(11):1687-700. Epub 2007 Jun 15. Review.

PMID:
17571260
10.

Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model.

Zacarías Fluck MF, Rico MJ, Gervasoni SI, Ilarregui JM, Toscano MA, Rabinovich GA, Scharovsky OG.

Cancer Immunol Immunother. 2007 Feb;56(2):237-48. Epub 2006 May 30.

PMID:
16733672

Supplemental Content

Loading ...
Support Center